This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Passage Bio’s 8K filing here.
About Passage Bio
Passage Bio, Inc, a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease.
Read More
- Five stocks we like better than Passage Bio
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- 3 Small Caps With Big Return Potential
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- What Makes a Stock a Good Dividend Stock?
- MarketBeat Week in Review – 10/21- 10/25
